Heterobicyclic Compounds Selective p38 Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for kinase-associated conditions, such as those involving p38 kinase, are limited in effectively inhibiting the activity of p38α and β isoforms, which are key mediators of inflammatory processes and cytokine production, leading to suboptimal management of inflammatory diseases.
Innovation Solution
Development of heterobicyclic compounds that act as selective inhibitors of p38 kinase, particularly targeting p38α and β isoforms, which are designed to reduce cytokine levels by modulating intracellular signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for kinase-associated conditions are used, then they are administered to patients, but they fail to effectively inhibit p38α and β isoforms, resulting in suboptimal management of inflammatory diseases
Solution Approach 1:
The patent applies local quality by designing heterobicyclic compounds with specific structural features (Formula I) that target particular regions or characteristics of the p38α and β kinase isoforms. The compounds contain specific heterobicyclic ring systems with particular substituent patterns that enable selective binding to the ATP-binding pockets of p38α and β isoforms, achieving localized and selective inhibition of these specific targets while sparing other kinase isoforms.
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters of the heterobicyclic compounds, including variations in ring structures, substituent types, and molecular properties. By adjusting these chemical parameters, the invention optimizes the compounds' affinity and selectivity for p38α and β isoforms, transforming general kinase inhibitors into selective p38 inhibitors with improved therapeutic effectiveness.
2Reliability
If heterobicyclic compounds are designed to selectively inhibit p38α and β isoforms, then cytokine production is reduced, but the complexity of the compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the heterobicyclic compound structure into distinct functional modules: a core heterobicyclic ring system (providing the essential pharmacophore), and variable substituent groups (R1-R6) that can be independently optimized. This modular segmentation allows chemists to systematically modify specific portions of the molecule to enhance selectivity for p38α and β isoforms without completely redesigning the entire molecular structure.
3Productivity
If current kinase inhibitors are used, then they are administered to treat inflammatory diseases, but they do not sufficiently reduce cytokine levels, leading to inadequate symptom relief
Solution Approach 1:
The patent employs the intermediary principle by using the heterobicyclic compounds as mediator molecules that specifically intervene in the signaling pathways involving p38α and β kinases. These compounds act as intermediary agents that block the phosphorylation cascade and downstream cytokine production without directly affecting the cytokines themselves, thereby efficiently reducing cytokine levels through indirect inhibition of the upstream kinase activity.
Data Source
AI summary
A compound of Formula (I)and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.